Colleague,

Without ensuring Payers, Patients and Prescribers receive cohesive and consistent messaging, patients will not gain access to innovative drugs, and pharma won’t be reimbursed. A truly multi-stakeholder approach needs to form the basis of commercial models.

In eyeforpharma’s latest white paper, “Balancing payers, patients and physicians: An integrated multi-stakeholder approach” Actelion, Pfizer, Bayer, Otsuka Pharmaceuticals, VClinBio and Salesforce share radical changes made to their organisational structure, which integrates their new approaches towards stakeholders.

The white paper, details:

• The shift of HCP’s from administrators of medicine to collaborators in patients care, and how pharma have changed engagement accordingly.

• How economic pressures have effected payer demands – giving them more clout in patient access.

• How to adapt outdated commercial models to enhance cross-functionality

Download this white paper here and see how to overcome the challenges of the new multi-stakeholder model, a revolution is not required.

I hope you find this content useful.

Best regards,

Izzy Gladstone,

Director, eyeforpharma

 

This email advertisement was sent on behalf of eyeforpharma by HealthEconomics.Com, 449 S. Mill View Way, Ponte Vedra Beach, FL 32082.
If you don't wish to receive further Industry Leaders News Updates from us, you may immediately unsubscribe from this list here , or send your request in writing to the address above. Read more about our privacy policy here. You may also request a copy in writing using the address above.